期刊
MEDICAL ONCOLOGY
卷 24, 期 1, 页码 71-75出版社
HUMANA PRESS INC
DOI: 10.1007/BF02685905
关键词
gastric cancer; chemotherapy; taxan; docetaxcel; 5'DFUR; second-line chemotherapy
类别
We conducted a clinical pilot study to evaluate the efficacy and safety of the combination of docetaxel and 5'DFUR as a second-line chemotherapy for gastric cancer. Twenty-four patients were divided into two groups by simple randomization: group A (60 mg/m(2) of docetaxel, every 3 wk) and group B (regimen A + 600 mg/body of 5'DFUR). The response rate was 17% and 42% in group A and B, respectively (p < 0.05). The MST from the start of the first-line was 17 mo in group B. The major adverse event was leukopenia in both groups.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据